Innoscripta (1INN) Q2 2026 earnings summary

Executive summary

• Revenue increased by up to 48.6% year-over-year in H1 2026, reaching as high as €65.3 million, with adjusted EBIT up 49% to €36.4 million and a margin of 57.7%.

• Customer base expanded to over 2,900, with churn rate below 2% and 97% of contracts set to auto-renew.

• International expansion initiated in France, UK, and US, targeting larger R&D tax credit markets.

• System migration (Clusterix) in Q1 temporarily delayed submissions and impacted Q2 revenue, but is now complete and expected to drive future efficiency and scalability.

• Full-year 2026 guidance confirmed at €140 million revenue and €80 million EBIT.

Financial highlights

• H1 2026 revenue grew up to 48.6% year-over-year to as high as €65.3 million, with gross profit at €63.1 million.

• Adjusted EBIT for H1 2026 reached €36.4 million, margin 57.7%, and net income rose 54% to €24.7 million.

• Free cash flow for H1 2026 was €39.8 million, representing 108.6% of adjusted EBITDA.

• Sales and marketing expenditure increased to €12.4 million, with efficiency gains reducing S&M to 19.6% of total performance.

• Dividend of €4.00 per share paid for FY 2025; €40 million distributed in H1 2026.

Outlook and guidance

• Full-year 2026 guidance reaffirmed: revenue of at least €140 million and EBIT of at least €80 million.

• Management expects continued strong growth in H2 2026, with rising funding applications and international expansion as key drivers.

• International markets expected to reach €1 million revenue within 12 months, with break-even at higher volumes.

• Addressable market significantly increased by entry into France, US, and UK, with €50 billion payout volume in new markets.